Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    "Multiple endocrine neoplasia type 2"
Show Display Options
RSS Create an RSS feed from your search for:
"Multiple endocrine neoplasia type 2"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B
Intervention: Drug: Vandetanib
2 Completed Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Conditions: Medullary Thyroid Carcinoma;   Multiple Endocrine Neoplasia Type 2
Intervention:
3 Active, not recruiting Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Regional Gastrointestinal Carcinoid Tumor;   Somatostatinoma;   WDHA Syndrome
Intervention: Drug: pazopanib hydrochloride

Indicates status has not been verified in more than two years